Registration 333-292283
- Gross proceeds
- 317700000.0
- Net proceeds
- 295461000.0
- Deal price
- 18.0
- Shares
- 17650000
- Offering price
- $18.00
- Ticker
- AKTS
Underwriters: J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen
Security
Aktis Oncology, Inc. Common stock · AKTS
AKTSNASDAQCommon stockCurrentCIK 2035832Updated Oct 6, 2026
AKTS price & chart
Loading TradingView…
NASDAQ:AKTS on TradingView ↗About the company
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure pa…
In the news
No coverage from other publishers is available.
Recent filings
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
144 filing
Show 5 more recent filings
Offerings
Filing attachments
ck0002035832-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors • Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer (mUC) and other Nectin-4 expressing solid tumors …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026 • Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments • Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 • Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026…
Read attachment ↗d110479dex991.htm · 8-K · 2026-04-16
EX-99.1 2 d110479dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors BOSTON - April 16, 2026 - Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results • Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations • Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSW…
Read attachment ↗ck0002035832-ex4_3.htm · 10-K · 2026-03-30
Exhibit 4.3 Description of Securities of Aktis Oncology, Inc. The following is a summary of the capital stock of Aktis Oncology, Inc. (“Aktis,” the “Company,” “our,” “we” or “us”) and certain provisions of our amended and restated certificate of incorporation (the “Restated Charter”), and our amended and restated bylaws (the “Restated Bylaws”), and certain provisions of Delaware law. This summary does not purport to be complete and is qualified by reference to our Restated Charter and Restated…
Read attachment ↗ex991.htm · SCHEDULE 13D · 2026-01-20
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigne…
Read attachment ↗